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Abstract
Background: Identifying characteristics associated with transcranial magnetic stimulation (TMS) benefit would offer
insight as to why some individuals experience tinnitus relief following TMS treatment, whereas others do not. The
purpose of this study was to use the Tinnitus Functional Index (TFI) and its subscales to identify specific factors
associated with TMS treatment responsiveness.
Methods: Individuals with bothersome tinnitus underwent 2000 pulses of 1-Hz TMS for 10 consecutive business
days. The primary outcome measure was the TFI which yields a total score and eight individual subscale scores.
Analyses were performed on baseline data from the active arm (n = 35) of a prospective, double-blind, randomized
placebo-controlled clinical trial of TMS for tinnitus.
Results: Baseline total TFI score and three of the eight TFI subscales were useful in differentiating between responders
and nonresponders to TMS intervention for tinnitus. These findings are not definitive, but suggest potential factors that
contribute to perceived benefit following TMS.
Conclusions: Overall, the main factor associated with TMS benefit was a higher tinnitus severity score for responders at
baseline. The TFI subscales helped to clarify the factors that contributed to a higher severity score at baseline. Large-
scale prospective research using systematic approaches is needed to identify and describe additional factors associated
with tinnitus benefit following TMS.
Trial registration: ClinicalTrials.gov, ID: NCT01104207. Registered on 13 April 2010.
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Background
Measures of tinnitus distress or severity are often used
to evaluate to what degree patients benefit from an
intervention. Unfortunately, the majority of instruments
designed to measure tinnitus severity were not devel-
oped to assess treatment outcomes [1]. Meikle et al. [2]
discuss the distinction between outcome measures de-
signed for screening purposes versus measures designed
to evaluate treatment responsiveness; that is, to detect
improvement over time. It is essential that the outcome
measures accurately assess the tinnitus severity (validity)
and do so with minimum error (reliability). Ideally, clini-
cians use an evidence-based approach in making a deci-
sion regarding the best method to assess tinnitus
therapy. Following the model of evidence-based medi-
cine allows clinicians to integrate their clinical expertise
with evidence from systematic research to guide their
decision-making on how best to evaluate and treat pa-
tients. However, evidence is lacking regarding the best
way to assess and treat tinnitus. Therefore, at the
current time, clinicians must rely mainly on their clinical
experiences and judgment regarding the best course of
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action to take when evaluating and treating tinnitus
patients.
Tinnitus therapy offers hope for patients by acknow-
ledging that their problem is not only “in their head”
and it is possible that something can be done to evaluate
and treat their condition. For many patients, any claim
of an effective tinnitus intervention, regardless of the
evidence, is worth pursuing. Unfortunately, there are
many experimental “treatments” promoted as effective
but without supporting evidence [3]. Well-designed clin-
ical trials demonstrating treatment efficacy need to be
conducted in order for these claims to be substantiated.
This issue raises the question of how best to determine
treatment effectiveness.
The Tinnitus Functional Index (TFI) is a relatively
new questionnaire, developed by Meikle et al. [4], with
the concept of responsiveness central to its design. The
TFI is a 25-item questionnaire that has good content
validity in terms of treatment responsiveness as well as
improved sensitivity for assessing tinnitus severity. The
TFI has a 0-to-10 response format for each question,
allowing for finer scaling of tinnitus severity (total pos-
sible TFI score ranges from 0 to 100). Another advan-
tage of the TFI is its ability to evaluate a broad array of
tinnitus-related problems by having a total of eight sub-
scales: Intrusive, Sense of Control, Cognitive, Sleep,
Auditory, Relaxation, Quality of Life, and Emotional.
The TFI has been validated psychometrically, showing
high internal consistency (Cronbach’s α = 0.98) and high
test-retest reliability (r = 0.91). Internal consistency and
test-retest reliability were also high for each of the eight
subscales with values ranging from α = 0.87–0.97 and r
= 0.71–0.92, respectively [4]. For additional information
on the design and suggested use of the TFI question-
naire, see Meikle et al. [4].
The aim of this substudy is to use the TFI to identify pa-
tient factors associated with responsiveness to transcranial
magnetic stimulation (TMS) treatment for tinnitus.
Mennemeier et al. [5] state the importance of investigating
factors associated with TMS treatment benefit to advance
the development of TMS as a treatment for tinnitus. TMS
has the potential to become an effective clinical interven-
tion for tinnitus sufferers. Identifying factors associated
with TMS responsiveness would allow the treatment to be
targeted to individuals most likely to experience benefit.
The purpose of this substudy is to use the TFI and its
subscales to identify factors across multiple domains of
tinnitus severity that are associated with patients’ respon-
siveness to TMS treatment for tinnitus.
Methods
Data reported and analyzed in this substudy are from a
prospective, double-blind, randomized placebo-controlled
clinical trial of repetitive TMS for tinnitus treatment [6].
Clinical trial methods
In the clinical trial, 70 subjects were randomly assigned
to receive either active or placebo TMS daily for 10 con-
secutive business days. Whether subjects received the
TMS procedure on the left or right side of the head was
also randomized. During each session of TMS, 2000
pulses of TMS were administered at a rate of 1 Hz.
Assessments were performed at baseline, immediately
following the last (10th) TMS session, and 1, 2, 4, 13,
and 26 weeks thereafter. The primary outcome measure
was the TFI.
Responder versus nonresponder
To determine whether a clinically significant change oc-
curred, TFI scores were examined immediately following
the 10th TMS session (i.e., post TMS) and compared to
baseline scores. An improvement of >7 TFI points was
used to classify a “responder” [6]. Using this criterion, 18
out of 35 subjects in the active TMS group were classi-
fied as responders and 9 out of 35 subjects in the pla-
cebo TMS group were classified as responders.
The placebo TMS coil used in the clinical trial pro-
duced sounds and sensations similar to the active TMS
coil. To better mimic the sounds and scalp sensations
perceived by subjects in the active TMS group, the pla-
cebo coil in the clinical trial was set to a relatively high
intensity, on average 60.8%. This stimulation intensity
makes it possible that our placebo coil was not com-
pletely “inert.” The placebo coil contains a metal plate
that supposedly interferes with the usual generation and
transmission of the magnetic field to the subjects’ brain.
Additional information about the placebo group and
other findings from the randomized clinical trial are re-
ported by Folmer et al. [6]. For this substudy, results
were calculated from baseline data comparing re-
sponders to nonresponders.
Methods: substudy
Subjects in the current substudy included 28 men and 7
women ranging in age from 32 to 73 years (mean = 58.5;
SD = 9.3). Only subjects randomized to the active arm of
the clinical trial were included (n = 35). To be consistent
with the clinical trial, the TFI was the primary outcome
measure used in this substudy. The criterion established
in the clinical trial for responders and nonresponders to
the TMS intervention was used in the current substudy.
The mean age of responders (n = 18) was 56.7 (SD =
10.9 years) and 60.5 (SD = 7.0 years) for nonresponders
(n = 17). No statistically significant differences were
found in age between responders and nonresponders.
Hearing ability
All degrees of sensorineural hearing loss were included
in the current substudy. Individuals with significant
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hearing loss who are bothered by their tinnitus are an
important subpopulation because often they do not
benefit from acoustic therapy to manage their tinnitus
and are, therefore, in need of an intervention (e.g., TMS)
that is not dependent on hearing ability.
Tinnitus characteristics
All subjects had constant, nonpulsatile tinnitus, of at
least 1 year in duration, which was self-rated at a loud-
ness of 6 or greater on a 0-to-10 visual numeric scale.
Laterality of tinnitus perception was not correlated with
TMS outcome (i.e., responder versus nonresponder) nor
with the TMS coil placement (i.e., left side versus right
side). Of the 18 subjects who responded to TMS,
perceived tinnitus location was reported as: in both ears
(n = 13), in the head (n = 2), dominant in the right ear
(n = 3), and dominant in the left ear (n = 0); of the 17
subjects who were classified as nonresponders, per-
ceived tinnitus location was reported as: in both ears
(n = 12), in the head (n = 2), dominant in the right ear
(n = 1), and dominant in the left ear (n = 2).
Data analysis
The data analyzed in this substudy were collected as part
of the parent clinical trial; therefore, no additional power
analysis was performed [6]. Comparisons were made be-
tween responders and nonresponders using independent
t tests. TFI total score and all eight subscale scores were
examined. To minimize the risk of multiple t tests (nine
in total) resulting in observing at least one significant
result due to chance, we applied the Bonferroni correc-
tion and adjusted the significance level to account for
this concern (p ≤ 0.01). Statistical analyses were con-
ducted using the Statistical Package for Social Sciences
Version 22.
Results
Table 1 displays the mean hearing thresholds for re-
sponders compared to nonresponders and the mean
audiograms are displayed in Fig. 1. There were no statisti-
cally significant differences in pure tone thresholds be-
tween these groups for any test frequencies.
Table 2 displays results and statistical analyses for re-
sponders compared to nonresponders at baseline on the
total TFI score and all TFI subscale scores. Of the eight
TFI subscales, the Auditory TFI subscale revealed a sta-
tistically significant difference for responders compared
to nonresponders, with responders showing higher
scores at baseline (p = 0.007); two other TFI subscales
approached statistical significance: Cognitive (p = 0.022)
and Emotional (p = 0.023) again showing higher severity
scores at baseline. TFI total score also approached sig-
nificance with responders having higher TFI total scores
at baseline (p = 0.017).
Discussion
The primary aim of this substudy was to use the TFI
and its subscales to identify specific factors associated
with TMS treatment-responsiveness for tinnitus. In gen-
eral, responders had higher overall tinnitus severity
scores at baseline compared to nonresponders. A higher
baseline severity score among treatment responders is
consistent with the findings of Lehner et al. [7]. Using a
different outcome measure of tinnitus severity, the
Tinnitus Questionnaire (TQ), Lehner et al. [7] reported
that subjects with higher TQ baseline scores showed
greater improvement following TMS treatment for tin-
nitus compared to subjects with lower TQ baseline
scores prior to treatment. Both the current substudy and
Table 1 Mean hearing thresholds (dB Hearing Level (dB HL)) for responders and nonresponders
Right ear (Hz) 250 500 1000 2000 3000 4000 6000 8000
Responders 20.00 (9.07) 20.56 (11.10) 21.67 (13.93) 30.56 (19.77) 42.50 (22.64) 49.44 (22.02) 55.28 (21.59) 56.67 (22.62)
Nonresponders 20.29 (9.10) 26.47 (16.28) 27.94 (18.96) 34.12 (21.30) 47.35 (22.78) 56.47 (21.63) 60.59 (21.71) 60.59 (20.61)
Left ear (Hz) 250 500 1000 2000 3000 4000 6000 8000
Responders 20.00 (9.39) 21.67 (11.50) 20.56 (13.27) 33.06 (20.23) 42.78 (22.24) 47.78 (20.16) 52.50 (18.65) 56.67 (22.94)







250 Hz 500 Hz 1000 Hz 2000 Hz 3000 Hz 4000 Hz 6000 Hz 8000 Hz
Responders RE Responders LE
Non-Responders RE Non-Responders LE
Fig. 1 Mean audiograms for responders and nonresponders. Legend:
Solid black lines with circles represent responders’ right ear mean
audiometric thresholds; solid black lines with “x” represent responders’ left
ear mean audiometric thresholds; dotted gray lines with circles represent
nonresponders’ right ear mean audiometric thresholds; dotted gray lines
with “x” represent nonresponders’ left ear mean audiometric thresholds
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Lehner et al. [7] showed baseline levels of tinnitus sever-
ity to be associated with TMS treatment responsiveness.
One advantage of using the TFI as the primary out-
come measure is that, of all the available tinnitus ques-
tionnaires, the TFI was specifically designed to measure
treatment responsiveness [4, 8]. The TFI is highly corre-
lated with the Tinnitus Handicap Inventory, but for the
purposes of identifying factors associated with treatment
responsiveness, it is imperative to use an instrument
developed and designed to specifically address this
psychometric property [1, 4].
Examining the TFI subscales allows for a greater un-
derstanding of the factors associated with the effective-
ness of specific tinnitus interventions [4]. The Auditory
TFI subscale showed significant differences between re-
sponders and nonresponders at baseline and assesses
perceptual difficulties individuals attribute to be related
to tinnitus. Specifically, questions in this subscale assess
the degree to which individuals believe that their tinnitus
interferes with their ability to hear, to understanding
what people are saying, and to follow the thread of a
conversation. By assessing a tinnitus patient’s ability to
follow conversations, the Auditory TFI subscale could
be indirectly sensitive to attentional problems. The Cog-
nitive TFI subscale is directly sensitive to attentional-
related problems associated with tinnitus such as the
ability to concentrate, to think clearly, and to focus
attention away from tinnitus. Both the Auditory and
Cognitive TFI subscales showed that responders to TMS
had higher severity scores on these subscales at baseline.
It is not uncommon for people with tinnitus and hear-
ing loss to attribute communication problems solely to
their tinnitus. In the current substudy, all subjects had
hearing loss (see Fig. 1). It is sometimes difficult for tin-
nitus patients to distinguish tinnitus-related problems
from hearing-related problems. When these conditions
co-occur, tinnitus is frequently “blamed” for the commu-
nication problems when, more than likely, the under-
lying hearing loss is more of a contributing factor
[9–11]. Tinnitus-related problems are often intertwined
with hearing-related problems, making it difficult to iso-
late one issue from the other. Henry et al. [12] addressed
this dilemma by developing the Tinnitus and Hearing
Survey, a brief questionnaire that is statistically validated
for differentiating tinnitus-related problems from hearing-
related problems. The Tinnitus and Hearing Survey
can be used as a counseling tool and can assist the
clinician in discussing with patients what appears to
be impacting daily functioning (e.g., tinnitus- versus
hearing-related problems).
The TFI Emotional subscale also exhibited meaningful
differences between responders and nonresponders at
baseline. This subscale evaluates the degree to which in-
dividuals feel anxious, bothered, and depressed because
of their tinnitus. People who have bothersome tinnitus
sometimes exhibit anxiety symptoms that may or may
not be clinically significant to the degree of qualifying as
an anxiety disorder. Severe tinnitus is often associated
with emotional distress, showing high correlations with
anxiety and depression [13].
Because TMS stimulates cortical structures, using
TMS to treat tinnitus might also result in other clinical
benefits. TMS produces a magnetic field which induces
an electric current in underlying neural tissue and ultim-
ately affects neuronal activity of structures in targeted
areas [14]. It is possible that, in addition to targeted cor-
tical structures, other neuronal networks, such as those
involved with attention, cognition, or auditory process-
ing, might also be affected during this process.
Conclusions
Differential effects of TMS for treatment of tinnitus have
been reported in multiple studies [15–17]. Findings from
the current substudy, along with results from Lehner
et al. [7], suggest that the degree of tinnitus severity at
baseline is associated with TMS treatment responsive-
ness. The TFI subscales offer valuable information and
point to specific factors that contribute to responding to
an intervention.
It is important to remember that this substudy recruited
individuals who had bothersome tinnitus. Examining
Table 2 TFI mean scores and independent t test results
TFI at baseline Mean (SD) Significance
(2-tailed)
Total score Responder 51.38 (18.69) 0.017
Nonresponder 36.73 (15.66)




Responder 62.59 (22.04) 0.223
Nonresponder 52.94 (23.98)
Cognitive subscale Responder 46.67 (25.08) 0.022
Nonresponder 26.86 (23.83)
Sleep subscale Responder 47.04 (28.21) 0.049
Nonresponder 27.65 (28.01)
Auditory subscale Responder 60.00 (15.88) 0.007a
Nonresponder 37.65 (27.02)
Relaxation subscale Responder 55.00 (28.43) 0.331
Nonresponder 46.27 (23.54)
Quality of Life subscale Responder 38.19 (24.14) 0.119
Nonresponder 25.44 (22.87)
Emotional subscale Responder 37.78 (25.13) 0.023
Nonresponder 20.59 (16.72)
ap ≤ 0.01; TFI Tinnitus Functional Index, SD Standard deviation
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overall TFI score at baseline is a good starting point, but
there is not an established “cutoff” score that separates in-
dividuals in need of help from those who do not. In
general, a more severe baseline score means an individual
has more room to improve following any form of inter-
vention or counseling. How we determine how much im-
provement following an intervention results in a clinically
significant change is a different matter.
Defining what “clinically significant change” is in terms
of treatment effects is not straightforward. Multiple
methods have been proposed addressing the concept of
clinical significance. Jacobson et al. [18] discuss various
methods for defining clinical significance and state,
“Clinical significance is routinely defined as returning to
normal functioning. Although for some disorders this
may be too stringent a criterion, it is based on the as-
sumption that consumers enter therapy expecting that
their presenting problems will be solved.” (p. 300).
A caveat when applying this to tinnitus interventions
is that widespread acceptance regarding what degree or
type of change is consistent with clinically significant
improvement does not exist. This quandary is not iso-
lated to tinnitus or the field of audiology. In the field of
psychology, Kazdin [19] puts forth the idea that clinical
significance can be interpreted in many different ways.
Kazdin makes an important point that the problem and
goals of treatment are influencing factors. Regarding tin-
nitus interventions, some goals focus on changing
characteristics of the tinnitus perception (e.g., pitch,
loudness) and other goals are directed at reducing
tinnitus-related distress, without any change in the tin-
nitus perception itself. Therefore, there are a multitude
of possible changes following tinnitus interventions that
can occur, all of which can contribute to whether or not
clinically significant change has occurred.
Tinnitus is complex and cannot be directly measured.
Therefore, it is challenging to define benefit in terms of
“solving the problem” because for some individuals the ex-
pectation is eliminating the tinnitus (i.e., finding a cure)
and for others it is obtaining some form of symptomatic
relief, but not necessarily quieting the tinnitus. An advan-
tage of using the TFI is the ability of its subscales to ex-
plain what “relief” looks like from the individuals’ point of
view in terms of improvement post intervention.
This substudy used the TFI to identify patient factors
associated with responsiveness to TMS for tinnitus.
Examining the differences between responders and non-
responders at baseline provides insight into possible fac-
tors associated with benefit using TMS for tinnitus.
Specifically, for this sample population, it suggests that
factors other than the tinnitus characteristics (e.g., loud-
ness) as captured by the elements on the Auditory,
Cognitive, and Emotional TFI subscales had an import-
ant influence on TMS outcome.
Limitations of current study
Due to the small sample size, the current study is limited
in terms of conducting complex data analyses. Prelimin-
ary results are compelling and, therefore, prospective re-
search using systematic approaches and larger numbers
of subjects is needed to identify predictive as well as
other factors that contribute to differentiating patient
responsiveness to TMS as an intervention for tinnitus.
Conducting these future studies is essential to
maximize the efficacy of TMS for tinnitus and to de-
termine if certain characteristics or factors would
identify certain individuals as ideal candidates for
responding to TMS for tinnitus.
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